Therapy | At study enrolment n=118 | Month 6 n=117 | Year 1 n=114 | Year 2 n=104 | Year 3 n=93 | Year 4 n=68 |
---|---|---|---|---|---|---|
No therapy, n (%) | 5 (4.2) | 31 (27.4) | 37 (35.9) | 47 (53.4) | 39 (56.5) | 41 (69.5) |
NSAID, n (%) | 101 (85.6) | 78 (66.7) | 60 (52.6) | 38 (35.5) | 25 (26.9) | 16 (23.5) |
csDMARD, n (%) | 48 (40.7) | 51 (43.6) | 45 (39.5) | 27 (25.2) | 17 (18.3) | 12 (17.6) |
Methotrexate, n (%) | 26 (22) | 25 (21.4) | 22 (19.3) | 11 (10.3) | 11 (11.8) | 8 (11.8) |
Sulfasalazine, n (%) | 17 (14.4) | 22 (18.8) | 18 (15.8) | 12 (11.2) | 5 (5.4) | 4 (5.9) |
bDMARD (TNFi), n (%) | 5 (4.2) | 5 (4.3) | 4 (3.5) | 6 (5.6) | 5 (5.4) | 4 (5.9) |
Combination NSAID and DMARDs, n (%) | 36 (30.5) | 31 (26.5) | 29 (25.4) | 18 (16.8) | 8 (8.6) | 5 (7.4) |
Glucocorticoids >0.2 mg/kg, n (%) | 10 (8.5) | 1 (0.9) | 1 (0.9) | 1 (0.9) | 1 (1.1) | 0 (0) |
Glucocorticoids ≤0.2 mg/kg, n (%) | 8 (6.8) | 6 (5.1) | 2 (1.8) | 2 (1.9) | 1 (1.1) | 1 (1.5) |
Glucocorticoids, intra-articular, n (%) | 18 (15.3) | 8 (6.8) | 4 (3.5) | 3 (2.8) | 2 (2.2) | 0 (0) |
bDMARD, biological disease-modifying antirheumatic drug; csDMARD, conventional synthetic disease-modifying antirheumatic drug; NSAID, non-steroidal anti-inflammatory drug; TNFi, tumour necrosis factor inhibitor.